<?xml version="1.0" encoding="UTF-8"?>
<boxed-text position="float" orientation="portrait">
 <caption>
  <title>Statement 8</title>
 </caption>
 <p>HBV status should be carefully monitored in patients with IBD who are positive for HBsAg or anti-HBc and treated using immunosuppressive therapy (strong recommendation, high evidence level). In patients who are positive for HBsAg, HBV DNA and ALT levels should be monitored every 3 to 6 months during prophylaxis, and for at least 12 months after cessation of anti-HBV prophylaxis (strong recommendation, low evidence level).</p>
 <p>Â· Level of agreement: strongly agree 47.5%, agree 52.5%, uncertain 0%, disagree 0% strongly disagree 0%</p>
</boxed-text>
